A phase II study of high-dose celecoxib and metronomic ‘low-dose‘ cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma
Authors:
- Tarek HashemTHTarek Hashem
- Hasan MetwallyHMHasan Metwally
- Ashraf Abd GhanyAGAshraf Abd Ghany
- Hager Abd El MageedHMHager Abd El Mageed
Open Access
- 1 January 2010
- journal article
- Published by Wolters Kluwer Health in Hematology/Oncology and Stem Cell Therapy
- Vol. 3 (1) , 13-17
Abstract
BACKGROUND AND OBJECTIVES: Relapsed, histologically aggressive non-Hodgkin lymphoma (NHL) has a poor prognosis; relapsed patients who do not respond to second line therapy or are unfit for BMT have a worse prognosis. Angiogenesis is increased in aggressive NHL and could be targeted by selective cyclooxygenase-2 inhhibition and metronomic chemotherapy. We assessed the toxicity of metronomic chemotherapy and the response and progression-free survival in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS: We prospectively studied 41 patients with a diagnosis of relapsed and/or refractory DLBCL who may have received any number of preceding therapies (as long as one included an anthracycline) and were not candidates for bone marrow transplantation. They received oral cyclophosphamide (50 mg every day), oral methotrexate (2.5 mg 4 times/week) and high-dose oral celecoxib (400 mg twice daily) until there was disease progression or unacceptable toxicity. RESULTS: All 41 patients (median age, 56 years) were evaluable for toxicity and response, with a median follow up of 9.1 months (range, 4-35 months). At relapse, 51.2% had a high international prognostic index. The treatment protocol was well tolerated with no major toxicities. The most common toxicities were fatigue (61%), nausea (22%), neutropenia (19.5%), and anemia (22%). In 31.7 % there was a partial response and 48.8% had stable disease. Progression-free survival was 12 months. The median response duration was 10 months. CONCLUSIONS: We conclude that metronomic chemotherapy can be used for patients with relapsed and or refractory DLBCL with reasonable outcome and acceptable toxicity. Standard approaches such as hematopoietic stem cell transplantation and chemo-immunotherapy combinations should be explored prior to a decision on metronomic chemotherapy.Keywords
This publication has 10 references indexed in Scilit:
- Salvage Therapy for Relapsed/Refractory Diffuse Large B Cell LymphomaTransplantation and Cellular Therapy, 2008
- Angiogenesis and antiangiogenic therapy in hematologic malignanciesCritical Reviews in Oncology/Hematology, 2007
- High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's LymphomaClinical Cancer Research, 2006
- Angiogenesis in malignant lymphomaCurrent Opinion in Oncology, 2005
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivoBlood, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphomaLeukemia Research, 2004
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's LymphomasJournal of Clinical Oncology, 1999
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995